Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amanat Acquisition Corp.AMAN · Entity 6741 | Director | May 18, 2026 | May 19, 2026 |
| NeuroPace IncNPCE · Entity 5459 | Director | June 19, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amanat Acquisition Corp.
Report date May 18, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | IndirectSee footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2026-05-18 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The reporting person beneficially owns 25,000 Class B ordinary shares which will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading "Description of Securities--Founder Shares and Private Placement Shares" in the Issuer's registration statement on Form S-1 (File No. 333-295170) ("Registration Statement") and have no expiration date. F2: For her services as a director, the Reporting Person receives indirect interest in founder shares through membership interests in the Company's sponsor, Amanat Sponsor Holdings LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person beneficially owns 25,000 Class B ordinary shares which will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading "Description of Securities--Founder Shares and Private Placement Shares" in the Issuer's registration statement on Form S-1 (File No. 333-295170) ("Registration Statement") and have no expiration date.
F2: For her services as a director, the Reporting Person receives indirect interest in founder shares through membership interests in the Company's sponsor, Amanat Sponsor Holdings LLC.
NeuroPace Inc
Report date June 19, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,039 |
Reported balance
After 2026-06-19 transaction · row 1
1 source rowRow 1 · 2026-06-19 · Grant · Acquired 989 · Balance 23,039 F1: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Roivant Sciences Ltd.
Report date February 20, 2025 · Filed February 25, 2025
Section 16 reporting ended · disclosed 2025-02-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 162,306 |
Reported balance
After 2025-02-20 transaction · row 1
1 source rowRow 1 · 2025-02-20 · Tax withholding · Disposed 958 · Balance 162,306 F1: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2023 Filed Sep 13, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 99,350 | $6.48 | $643,788.00 |
DisclosureSEC source: 0001140361-23-043730 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 297,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 05, 2023 Filed Sep 8, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,724 | $0.00 Strike: $6.48 | $0.00 |
DisclosureSEC source: 0001140361-23-043270 · form4.xml · derivative · entry 3 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,350 Underlying: Common Shares · 1,724 shares Expires 2027-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of May 20, 2017. The award of stock options is fully vested. Read SEC document |
| September 05, 2023 Filed Sep 8, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 1,724 | $12.00 | $20,688.00 |
DisclosureSEC source: 0001140361-23-043270 · form4.xml · nonDerivative · entry 2 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,950 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| September 05, 2023 Filed Sep 8, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 1,724 | $6.48 | $11,171.52 |
DisclosureSEC source: 0001140361-23-043270 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,674 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 22, 2023 Filed Aug 25, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 1,378 | $10.83 | $14,923.74 |
DisclosureSEC source: 0001140361-23-041199 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,950 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| August 03, 2023 Filed Aug 4, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,681 | $0.00 Strike: $6.48 | $0.00 |
DisclosureSEC source: 0001140361-23-037941 · form4.xml · derivative · entry 6 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,074 Underlying: Common Shares · 3,681 shares Expires 2027-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares. The award of stock options is fully vested. Read SEC document |
| August 03, 2023 Filed Aug 4, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 3,681 | $12.00 | $44,172.00 |
DisclosureSEC source: 0001140361-23-037941 · form4.xml · nonDerivative · entry 4 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,328 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| August 03, 2023 Filed Aug 4, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 3,681 | $6.48 | $23,852.88 |
DisclosureSEC source: 0001140361-23-037941 · form4.xml · nonDerivative · entry 3 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2023 Filed Aug 4, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 336 | $0.00 Strike: $6.48 | $0.00 |
DisclosureSEC source: 0001140361-23-037941 · form4.xml · derivative · entry 5 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,755 Underlying: Common Shares · 336 shares Expires 2027-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares. The award of stock options is fully vested. Read SEC document |
| August 01, 2023 Filed Aug 4, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 336 | $12.00 | $4,032.00 |
DisclosureSEC source: 0001140361-23-037941 · form4.xml · nonDerivative · entry 2 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,328 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| August 01, 2023 Filed Aug 4, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 336 | $6.48 | $2,177.28 |
DisclosureSEC source: 0001140361-23-037941 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 24, 2023 Filed Jul 27, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 1,393 | $10.99 | $15,309.07 |
DisclosureSEC source: 0001140361-23-036309 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,328 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| July 18, 2023 Filed Jul 19, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100 | $0.00 Strike: $6.48 | $0.00 |
DisclosureSEC source: 0001140361-23-035096 · form4.xml · derivative · entry 6 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,091 Underlying: Common Shares · 100 shares Expires 2027-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of May 20, 2017. The award of stock options is fully vested. Read SEC document |
| July 18, 2023 Filed Jul 19, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 100 | $12.00 | $1,200.00 |
DisclosureSEC source: 0001140361-23-035096 · form4.xml · nonDerivative · entry 4 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,128 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. F2 · balance_after: Includes Common Shares purchased under the Company's Employee Stock Purchase Plan. Read SEC document |
| July 18, 2023 Filed Jul 19, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 100 | $6.48 | $648.00 |
DisclosureSEC source: 0001140361-23-035096 · form4.xml · nonDerivative · entry 3 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes Common Shares purchased under the Company's Employee Stock Purchase Plan. Read SEC document |
| July 14, 2023 Filed Jul 19, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 535 | $0.00 Strike: $6.48 | $0.00 |
DisclosureSEC source: 0001140361-23-035096 · form4.xml · derivative · entry 5 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,191 Underlying: Common Shares · 535 shares Expires 2027-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of May 20, 2017. The award of stock options is fully vested. Read SEC document |
| July 14, 2023 Filed Jul 19, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 535 | $12.00 | $6,420.00 |
DisclosureSEC source: 0001140361-23-035096 · form4.xml · nonDerivative · entry 2 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,128 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. F2 · balance_after: Includes Common Shares purchased under the Company's Employee Stock Purchase Plan. Read SEC document |
| July 14, 2023 Filed Jul 19, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 535 | $6.48 | $3,466.80 |
DisclosureSEC source: 0001140361-23-035096 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,663 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes Common Shares purchased under the Company's Employee Stock Purchase Plan. Read SEC document |
| June 30, 2023 Filed Jun 24, 2025 20:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 3,340 | $4.49 | $14,996.60 |
DisclosureSEC source: 0001415889-25-018089 · form4-06242025_040603.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,340 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| June 22, 2023 Filed Jun 27, 2023 01:31 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 1,357 | $10.01 | $13,583.57 |
DisclosureSEC source: 0001140361-23-031546 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,225 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| June 09, 2023 Filed Jun 14, 2023 01:31 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 43,893 | $0.00 Strike: $5.12 | $0.00 |
DisclosureSEC source: 0001140361-23-029728 · form4.xml · derivative · entry 3 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 43,893 shares Expires 2025-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of December 30, 2015. The award of stock options is fully vested. Read SEC document |
| June 09, 2023 Filed Jun 14, 2023 01:31 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 43,893 | $9.93 | $435,857.49 |
DisclosureSEC source: 0001140361-23-029728 · form4.xml · nonDerivative · entry 2 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,582 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| June 09, 2023 Filed Jun 14, 2023 01:31 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 43,893 | $5.12 | $224,732.16 |
DisclosureSEC source: 0001140361-23-029728 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 242,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2023 Filed Jun 14, 2023 20:56 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantStock Option (Rt to Buy) · Derivative | 27,380 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001209191-23-037074 · doc4.xml · derivative · entry 1 Kumar Rakhi · CIK 0001856296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,380 Underlying: Common Stock · 27,380 shares Expires 2033-06-06 F1 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable. Read SEC document |
| May 23, 2023 Filed May 26, 2023 01:31 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 1,557 | $9.58 | $14,916.06 |
DisclosureSEC source: 0001140361-23-026782 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,582 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| May 02, 2023 Filed May 4, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,517 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-022809 · form4.xml · derivative · entry 6 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Shares · 15,517 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| May 02, 2023 Filed May 4, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 15,517 | $8.42 | $130,653.14 |
DisclosureSEC source: 0001140361-23-022809 · form4.xml · nonDerivative · entry 4 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200,139 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| May 02, 2023 Filed May 4, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 15,517 | $3.85 | $59,740.45 |
DisclosureSEC source: 0001140361-23-022809 · form4.xml · nonDerivative · entry 3 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 215,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2023 Filed May 4, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 62,219 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-022809 · form4.xml · derivative · entry 5 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 765,517 Underlying: Common Shares · 62,219 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| May 01, 2023 Filed May 4, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 62,219 | $8.58 | $533,839.02 |
DisclosureSEC source: 0001140361-23-022809 · form4.xml · nonDerivative · entry 2 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200,139 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| May 01, 2023 Filed May 4, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 62,219 | $3.85 | $239,543.15 |
DisclosureSEC source: 0001140361-23-022809 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 262,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2023 Filed Apr 29, 2023 01:35 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 71,989 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-021749 · form4.xml · derivative · entry 13 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 827,736 Underlying: Common Shares · 71,989 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| April 28, 2023 Filed Apr 29, 2023 01:35 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 71,989 | $8.47 | $609,746.83 |
DisclosureSEC source: 0001140361-23-021749 · form4.xml · nonDerivative · entry 8 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200,139 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| April 28, 2023 Filed Apr 29, 2023 01:35 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 71,989 | $3.85 | $277,157.65 |
DisclosureSEC source: 0001140361-23-021749 · form4.xml · nonDerivative · entry 7 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 272,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 27, 2023 Filed Apr 29, 2023 01:35 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 65,634 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-021749 · form4.xml · derivative · entry 12 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 899,725 Underlying: Common Shares · 65,634 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| April 27, 2023 Filed Apr 29, 2023 01:35 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,335 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0001140361-23-021749 · form4.xml · derivative · entry 11 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,335 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares that was fully vested. Read SEC document |
| April 27, 2023 Filed Apr 29, 2023 01:35 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 70,969 | $8.51 | $603,946.19 |
DisclosureSEC source: 0001140361-23-021749 · form4.xml · nonDerivative · entry 6 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200,139 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| April 27, 2023 Filed Apr 29, 2023 01:35 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 65,634 | $3.85 | $252,690.90 |
DisclosureSEC source: 0001140361-23-021749 · form4.xml · nonDerivative · entry 5 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 271,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 27, 2023 Filed Apr 29, 2023 01:35 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 5,335 | $3.97 | $21,179.95 |
DisclosureSEC source: 0001140361-23-021749 · form4.xml · nonDerivative · entry 4 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 26, 2023 Filed Apr 29, 2023 01:35 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 34,641 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-021749 · form4.xml · derivative · entry 10 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 965,359 Underlying: Common Shares · 34,641 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| April 26, 2023 Filed Apr 29, 2023 01:35 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 53,189 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0001140361-23-021749 · form4.xml · derivative · entry 9 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,335 Underlying: Common Shares · 53,189 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares that was fully vested. Read SEC document |
| April 26, 2023 Filed Apr 29, 2023 01:35 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 87,830 | $8.68 | $762,364.40 |
DisclosureSEC source: 0001140361-23-021749 · form4.xml · nonDerivative · entry 3 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200,139 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| April 26, 2023 Filed Apr 29, 2023 01:35 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 34,641 | $3.85 | $133,367.85 |
DisclosureSEC source: 0001140361-23-021749 · form4.xml · nonDerivative · entry 2 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 287,969 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 26, 2023 Filed Apr 29, 2023 01:35 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 53,189 | $3.97 | $211,160.33 |
DisclosureSEC source: 0001140361-23-021749 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 253,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 20, 2023 Filed Apr 25, 2023 01:28 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantStock Option (Right to Buy) · Derivative | 286,408 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001140361-23-019992 · form4.xml · derivative · entry 3 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286,408 Underlying: Common Shares · 286,408 shares Expires 2033-04-19 F4 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2023. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date. Read SEC document |
| April 20, 2023 Filed Apr 25, 2023 01:28 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 1,569 | $8.80 | $13,807.20 |
DisclosureSEC source: 0001140361-23-019992 · form4.xml · nonDerivative · entry 2 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,139 F3 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. F2 · balance_after: Includes Common Shares purchased under the Company's Employee Stock Purchase Plan. Read SEC document |
| April 20, 2023 Filed Apr 25, 2023 01:28 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 66,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-019992 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,708 F1 · shares: Reflects an award of 66,710 restricted stock units with respect to Common Shares ("RSUs") with a vesting commencement date of April 20, 2023. 1/4 of the RSUs service-vest twelve (12) months after the vesting commencement date; 1/16 of the RSUs service-vest fourteen (14) months after the vesting commencement date; and the balance of the RSUs service-vest in a series of eleven (11) successive equal quarterly installments measured from the date fourteen (14) months after the vesting commencement date, subject to the reporting person's Continuous Service through the applicable vesting date. F2 · balance_after: Includes Common Shares purchased under the Company's Employee Stock Purchase Plan. Read SEC document |
| March 23, 2023 Filed Mar 28, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 2,134 | $7.30 | $15,578.20 |
DisclosureSEC source: 0001140361-23-014075 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,409 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 02:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 1,797 | $8.43 | $15,148.71 |
DisclosureSEC source: 0001140361-23-008668 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,543 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| January 24, 2023 Filed Jan 27, 2023 02:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 1,838 | $8.56 | $15,733.28 |
DisclosureSEC source: 0001140361-23-002959 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,340 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.